Biofrontera AG: FDA grants approval for Ameluz® in the USA

Leverkusen (pta004/11.05.2016/03:15 UTC+2) Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, has received unconditional approval for marketing in the US from the Food and Drug Administration FDA for its prescription drug Ameluz® in combination with the PDT-lamp BF-RhodoLED® for the lesion-directed and field-directed treatment of mild to moderate actinic keratoses on the face and the scalp. FDA has not requested any post-approval obligations.

Further details shall be disclosed in a separate announcement shortly.

Leverkusen, May 11, 2016
The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor & public relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	press@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart